(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041846 A2

(51) International Patent Classification[7]: C07K

(21) International Application Number:
PCT/US2003/034818

(22) International Filing Date: 31 October 2003 (31.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/423,297 1 November 2002 (01.11.2002) US

(71) Applicant: **BOYS TOWN NATIONAL RESEARCH HOSPITAL** [US/US]; 555 North 30th Street, Omaha, NE 68131 (US).

(72) Inventor: **COSGROVE, Dominic**; 5612 Howard Street, Omaha, NE 68106 (US).

(74) Agent: **MUETING, Ann, M.**; Mueting, Raasch & Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/041846 A2

(54) Title: INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES

(57) Abstract: The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin.